Influenza A vaccine intranasal - Altimmune

Drug Profile

Influenza A vaccine intranasal - Altimmune

Alternative Names: ADhVN1203/04.H5; Influenza A vaccine H5N1 - Altimmune; Influenza-virus-vaccine-Vaxin; NasoVAX; Seasonal-influenza-virus-vaccine-intranasal-Vaxin

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype

Most Recent Events

  • 27 Mar 2018 Altimmune plans a challenge trial of quadrivalent vaccine for Influenza A virus (Prevention) in early 2019
  • 27 Mar 2018 Immunogenicity and safety data from a phase IIa trial in Influenza released by Altimmune
  • 20 Sep 2017 Phase-II clinical trials in Influenza-A virus H5N1 subtype (Prevention) in USA (Intranasal) (NCT03232567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top